| Primary |
| Deep Vein Thrombosis |
19.9% |
| Atrial Fibrillation |
18.1% |
| Pulmonary Embolism |
11.9% |
| Thrombosis Prophylaxis |
9.3% |
| Hypertension |
6.2% |
| Sedation |
4.4% |
| Prophylaxis |
4.0% |
| Acute Coronary Syndrome |
3.5% |
| Pain |
2.7% |
| Anticoagulant Therapy |
2.2% |
| Cerebrovascular Accident |
2.2% |
| Dvt Prophylaxis |
2.2% |
| Surgery |
2.2% |
| Thrombosis |
2.2% |
| Aortic Valve Disease |
1.8% |
| Drug Therapy |
1.8% |
| Analgesic Effect |
1.3% |
| Angina Unstable |
1.3% |
| Antiphospholipid Syndrome |
1.3% |
| Asthma |
1.3% |
|
| Haematoma |
14.3% |
| Haemorrhage |
12.2% |
| Thrombocytopenia |
10.2% |
| Subdural Haematoma |
6.1% |
| Maternal Exposure During Pregnancy |
5.1% |
| Gastric Haemorrhage |
4.1% |
| Haemoglobin Decreased |
4.1% |
| Heparin-induced Thrombocytopenia |
4.1% |
| Hepatic Enzyme Increased |
4.1% |
| Hypotension |
4.1% |
| Retroperitoneal Haematoma |
4.1% |
| Abdominal Wall Haematoma |
3.1% |
| Death |
3.1% |
| Deep Vein Thrombosis |
3.1% |
| Injection Site Haematoma |
3.1% |
| Injury Associated With Device |
3.1% |
| Pelvic Haematoma |
3.1% |
| Pulmonary Embolism |
3.1% |
| Renal Failure Acute |
3.1% |
| Shock Haemorrhagic |
3.1% |
|
| Secondary |
| Product Used For Unknown Indication |
41.5% |
| Drug Abuse |
15.9% |
| Thrombosis Prophylaxis |
5.5% |
| Deep Vein Thrombosis |
4.9% |
| Drug Use For Unknown Indication |
4.7% |
| Pulmonary Embolism |
4.4% |
| Acute Myocardial Infarction |
4.0% |
| Atrial Fibrillation |
3.1% |
| Embolism |
2.9% |
| Acute Coronary Syndrome |
1.9% |
| Anticoagulant Therapy |
1.9% |
| Prophylaxis |
1.4% |
| Hypertension |
1.3% |
| Pulmonary Arterial Hypertension |
1.3% |
| Lupus Nephritis |
1.1% |
| Myocardial Infarction |
1.1% |
| Thrombosis |
1.0% |
| Antiplatelet Therapy |
0.7% |
| Cerebrovascular Accident Prophylaxis |
0.7% |
| Hip Surgery |
0.7% |
|
| Wrong Technique In Drug Usage Process |
8.2% |
| Haemorrhage |
6.4% |
| International Normalised Ratio Increased |
6.4% |
| Deep Vein Thrombosis |
5.5% |
| Fatigue |
5.5% |
| Gastrointestinal Haemorrhage |
5.5% |
| Haemoglobin Decreased |
5.5% |
| International Normalised Ratio Decreased |
5.5% |
| Premature Baby |
5.5% |
| Haemorrhage Intracranial |
4.5% |
| Ischaemic Stroke |
4.5% |
| Pain |
4.5% |
| Splenic Rupture |
4.5% |
| Subdural Haemorrhage |
4.5% |
| Thrombocytopenia |
4.5% |
| Transient Ischaemic Attack |
4.5% |
| Gastric Haemorrhage |
3.6% |
| No Adverse Event |
3.6% |
| Pulmonary Embolism |
3.6% |
| Retroperitoneal Haemorrhage |
3.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.8% |
| Prophylaxis |
8.2% |
| Drug Use For Unknown Indication |
7.2% |
| Hypertension |
5.4% |
| Pain |
5.1% |
| Thrombosis Prophylaxis |
3.9% |
| Adverse Event |
3.8% |
| Nausea |
2.8% |
| Atrial Fibrillation |
2.7% |
| Multiple Myeloma |
2.4% |
| Plasma Cell Myeloma |
2.4% |
| Prostate Cancer |
2.3% |
| Chronic Obstructive Pulmonary Disease |
1.9% |
| Acute Coronary Syndrome |
1.9% |
| Acute Myocardial Infarction |
1.9% |
| Infection |
1.8% |
| Non-small Cell Lung Cancer |
1.7% |
| Osteoporosis |
1.7% |
| Rheumatoid Arthritis |
1.6% |
| Diabetes Mellitus |
1.5% |
|
| Pneumonia |
10.6% |
| Pulmonary Embolism |
10.0% |
| Death |
9.8% |
| Renal Failure Acute |
6.7% |
| Pyrexia |
6.5% |
| Vomiting |
5.5% |
| Thrombocytopenia |
4.9% |
| Deep Vein Thrombosis |
4.3% |
| Pain |
4.1% |
| Urinary Tract Infection |
4.1% |
| Sepsis |
3.9% |
| Dyspnoea |
3.7% |
| Fatigue |
3.7% |
| Neutropenia |
3.7% |
| Weight Decreased |
3.5% |
| Myocardial Infarction |
3.3% |
| Hepatic Enzyme Increased |
3.1% |
| Renal Failure |
3.1% |
| Unresponsive To Stimuli |
3.1% |
| Respiratory Failure |
2.9% |
|
| Interacting |
| Product Used For Unknown Indication |
31.6% |
| Acute Coronary Syndrome |
10.5% |
| Atrial Fibrillation |
10.5% |
| Prophylaxis |
7.0% |
| Cerebrovascular Accident Prophylaxis |
5.3% |
| Myocardial Ischaemia |
5.3% |
| Pain |
5.3% |
| Coronary Artery Disease |
3.5% |
| Diabetes Mellitus |
3.5% |
| Thrombosis Prophylaxis |
3.5% |
| Abdominal Pain Upper |
1.8% |
| Acute Myeloid Leukaemia |
1.8% |
| Anaemia |
1.8% |
| Anticoagulant Therapy |
1.8% |
| Arterial Catheterisation |
1.8% |
| Hypertension |
1.8% |
| Pulmonary Embolism |
1.8% |
| Transient Ischaemic Attack |
1.8% |
|
| Anastomotic Ulcer Haemorrhage |
25.0% |
| Gastrointestinal Haemorrhage |
8.3% |
| Haematochezia |
8.3% |
| Pleural Effusion |
8.3% |
| Pneumonia Bacterial |
8.3% |
| Product Substitution Issue |
8.3% |
| Pulmonary Embolism |
8.3% |
| Respiratory Tract Infection |
8.3% |
| Retroperitoneal Haematoma |
8.3% |
| Subdural Haematoma |
8.3% |
|
